Decreased exposure & C
max w/ strong & moderate CYP3A4 & P-gp inducers (eg, carbamazepine, phenobarb, St. John's Wort, phenytoin, rifampicin). Increased exposure w/ combined P-gp & strong CYP3A4 inhibitor. Increased exposure & C
max of rosuvastatin. May increase plasma conc of other concomitant BCRP, OATP1B1 & OATP1B3 substrates (eg, methotrexate, sulfasalazine, fluvastatin, atorvastatin, pitavastatin). Decreased exposure & C
max of midazolam (sensitive CYP3A4 substrate). Additive effect on QT interval w/ medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de pointes eg, class IA or III antiarrhythmics, methadone, moxifloxacin, antipsychotics (eg, haloperidol).